Stone Richard M
Harvard Medical School, Boston, MA 02215, USA; Adult Leukemia Program, Dana-Farber Cancer Institute, 450 Brookline Avenue, D2053, Boston, MA 02215, USA.
Best Pract Res Clin Haematol. 2017 Dec;30(4):312-316. doi: 10.1016/j.beha.2017.09.006. Epub 2017 Sep 22.
For 4 decades, new agents had not been permanently approved for use in treating acute myeloid leukemia (AML). The long dry spell was broken in 2017, however, with the approval of several agents: midostaurin for addition to chemotherapy in mutant FLT3 patients undergoing intensive chemotherapy, enasidenib in advanced mutant IDH2 patients, CPX-351 in secondary AML patients, and gemtuzumab ozogamicin in conjunction with standard chemotherapy in AML. This review surveys the use of tyrosine kinase inhibitors to treat patients with mutant FLT3 AML, mutant KIT AML, as well as IDH inhibitors and explores some questions regarding their integration into the treatment armamentarium for AML.
四十年来，一直没有新的药物被永久批准用于治疗急性髓系白血病（AML）。然而，2017年这一漫长的空白期被打破，有几种药物获得批准：米哚妥林用于接受强化化疗的FLT3突变患者，与化疗联合使用；恩杂鲁胺用于晚期IDH2突变患者；CPX-351用于继发性AML患者；吉妥珠单抗奥唑米星与AML的标准化疗联合使用。本综述探讨了酪氨酸激酶抑制剂在治疗FLT3突变AML患者、KIT突变AML患者中的应用，以及IDH抑制剂，并探讨了将它们纳入AML治疗方案的一些问题。
